Point-of-care testing for bacterial infection in diabetic foot ulcers: a prospective cohort study by Jonker, Leon et al.
Jonker,  Leon,  S mit h,  Da nielle,  M a rk,  E m m a,  Sc h u t t er,  Jose,  
Tho r n t h w ai t e ,  S a r a h  a n d  Johns ton,  S ho n a  (202 0)  Point-of-c a r e  
t e s ting  for  b a c t e ri al  infec tion  in  dia b e tic  foot  ulce r s:  a  
p ros p ec tive  coho r t  s t u dy.  Jou r n al  of  Woun d  Ca r e ,  2 9  (11).  p p .  
6 4 9-6 5 7.  
Downloa d e d  fro m: h t t p://insig h t .c u m b ri a. ac.uk/id/e p rin t/5 7 8 1/
U s a g e  o f  a n y  i t e m s  fr o m  t h e  U n i v e r s i t y  o f  C u m b r i a’ s  i n s t i t u t i o n a l  r e p o s i t o r y  
‘In s i g h t’  m u s t  c o nf o r m  t o  t h e  f o l l o w i n g  f a i r  u s a g e  g u i d e l i n e s .
Any  ite m  a n d  its  a s socia t e d  m e t a d a t a  h eld  in  t h e  U nive rsi ty  of  Cu m b ria ’s in s ti t u tion al  
r e posi to ry  Insig h t  (unles s  s t a t e d  o th e r wis e  on  t h e  m e t a d a t a  r e co r d)  m ay  b e  copied,  
di spl aye d  o r  p e rfo r m e d,  a n d  s to r e d  in  line  wit h  t h e  JISC  fair  d e aling  g uid eline s  (available  
h e r e ) for  e d u c a tion al a n d  no t-for-p r ofit  a c tivitie s
pr ovid e d  t h a t
•  t h e  a u t h o r s ,  ti tl e  a n d  full bibliog r a p hic  d e t ails  of t h e  it e m  a r e  ci t e d  cle a rly w h e n  a ny  
p a r t
of t h e  wo rk  is r ef e r r e d  to  ve r b ally o r  in  t h e  w ri t t e n  for m  
•  a  hyp e rlink/URL  to  t h e  o rigin al  Insig h t  r e co r d  of  t h a t  it e m  is  inclu d e d  in  a ny  
ci t a tions  of t h e  wo rk
•  t h e  co n t e n t  is  no t  c h a n g e d  in a ny  w ay
•  all file s  r e q ui r e d  for  u s a g e  of t h e  it e m  a r e  k ep t  tog e t h e r  wi th  t h e  m ain  it e m  file.
You m a y  n o t
•  s ell a ny  p a r t  of a n  it e m
•  r efe r  to  a ny  p a r t  of a n  it e m  witho u t  ci t a tion
•  a m e n d  a ny  it e m  o r  con t ext u alise  it  in  a  w ay  t h a t  will  imp u g n  t h e  c r e a to r ’s 
r e p u t a tion
•  r e m ov e  o r  al t e r  t h e  co pyrig h t  s t a t e m e n t  on  a n  it e m.
Th e  full policy ca n  b e  fou n d  h e r e . 
Alt e r n a tively  con t ac t  t h e  U nive r si ty  of  Cu m b ria  Re posi to ry  E di to r  by  e m ailing  
insig h t@cu m b ria. ac.uk .
Title: A single-centre, prospective cohort study assessing the proprietary Glycologic test kit 
to detect bacterial infection in diabetic foot ulcers; prospects for point-of-care testing.. 
Running title: Point-of-care infection testing for DFU  
Authors: Leon Jonker, Danielle Smith, Emma Mark, Jose Schutter, Sarah Thornthwaite, 
Shona Johnston.     
Abstract 
Aims. To appraise the performance of a new point-of-care wound infection detection kit in 
diabetic foot ulcers (DFU), using clinician opinion as the primary comparator. The 
proprietary swab-based chromatic Glycologic detection kit is designed to detect host-
response to pathogenic levels of bacteria in wounds. 
Methods. In high-risk podiatry clinics, 136 DFU patients were recruited and Glycologic test 
result compared to initial clinician opinion. Chi-squared test, principal component analysis 
(PCA) and multiple regression analysis were performed to determine which variables are 
possibly associated with infection. Variables were patients’ wound parameters, wider 
vascular co-morbidity, and demographics. 
Results: Total agreement in terms of DFU wound assessment for infection – between 
podiatrists’ clinical opinion and Glycologic kit test result - was observed in 79% of cases (301 
out of 383 wound assessments), whereas podiatrists identified more (possible) infections 
than the Glycologic kit (55 [15%] vs 14 [4%] swabs respectively). Regression analysis and PCA 
showed that clinical signs of wound infection, namely erythema, purulence, and odour, are 
all significantly associated with both a positive clinical opinion and Glycologic test result. 
However, in case of the Glycologic kit a patient’s number of lesions and vascular 
comorbidities are also significantly correlated with a change in colour. 
Conclusion: A host-response to critical pathological levels of bioburden in a wound – as 
detected with the Glycologic test kit – may partly be determined by an individual patient’s 
(vascular) health and therefore be person-specific. Further research is indicated to 
determine the relationship between a Glycologic test result and the microbiological status 
of the wound. 
Acknowledgements: 
We are grateful to the North, East and West Cumbria podiatry teams at Cumbria Partnership 
NHS Foundation Trust for accommodating and supporting the study.  
Conflicts of interest: None of the authors have any conflict of interest to declare. 
Sources of funding: A non-restricted research grant, through provision of the Glycologic test 









Diabetic foot ulcers (DFU) are a common complication of diabetes and have enormous cost 
implications, totalling £650 million per year once associated morbidity is taken into 
account.1 Bacterial infection of wounds carries the risk of further degenerative 
complications including cellulitis, necrotising fasciitis, and sepsis; it may lead to amputation 
if osteomyelitis develops.2  An additional undesirable effect of infection of wounds is that it 
delays – or stops altogether – the wound healing process.3  
Detection of DFU infection remains predominantly reliant on clinical judgement. O’Meara 
and colleagues4 concluded from a systematic review on clinical examination, sample 
acquisition and sample analysis in DFUs that there is a lack of evidence regarding what 
samples should be taken and how they should be analysed. They also suggested that semi-
quantitative sample analysis could be a useful alternative to quantitative analysis. 
Quantitative detection of infection is relatively costly and labour intensive5; it is still 
predominantly undertaken by swabbing the wound, rather than arguably superior tissue 
sampling6, and then culturing the pathogens in a microbiology laboratory. Obtaining these 
results generally takes days, and even molecular profiling does not give an instant result, 
which hampers clinicians in making in an instant informed decision on wound management; 
instead, recommended first line antibiotic therapy may be initiated without knowing the 
sensitivity results. Microbiological counts and species identification – though used for 
sensitivity testing if there is indeed an infection present - do not necessarily reflect infection 
as defined by other assessments, as demonstrated by Gardner et al.7   
Clinical guidelines stipulate that the only available laboratory-based diagnostic option, 
microbiological testing, should only be used to identify the pathogen strain in clinically 
confirmed infection. Therefore, clinical opinion is the mainstay of the initial diagnosis of 
infection.8,9  The lack of a simple cost-effective and repeatable point-of-care testing method 
may have three consequences: 1) potential for lack of uniformity in diagnosis, due to 
differences in clinical judgement, which in turn may result in 2) over-diagnosis of infection 
with inappropriate prescription of antibiotics or antimicrobial dressings, or 3) under-
diagnosis and subsequent late presentation of patients with systemic signs and spreading 
cellulitis or osteomyelitis requiring hospital admission and treatment with intravenous 
antibiotics or emergency surgery. The provision of a rapid, reliable, accurate and relatively 
low-cost point-of-care infection detection test kit could potentially provide cost savings as 
well as improve clinical outcomes for patients. 
Glycologic Ltd has developed a proprietary swab-based chromatic point-of-care test, in 
which a clear solution changes to either yellow or orange within a 10 minute incubation of 
the wound swab at room temperature. Although the company is not in a position to disclose 
the exact mechanism of action at this point, the reaction involves a patient-derived 
molecule implicated in host-response to a pathological infection and not the 
microorganisms present in the wound. This therefore does not necessarily mean the 
quantity/reactivity of this molecule is linearly correlated with the quantity of bioburden in a 
wound. In this study we appraise the performance of the Glycologic infection detection kit 
in terms of comparison of outcomes when compared to clinicians’ opinion of DFU infection 
and results obtained with the kit.  
 
 
Patients & methods 
Study design and patients 
This concerns a controlled, non-randomised, single-blinded, prospective comparative study 
of the Glycologic detection kit versus clinical judgement of DFU infection status, carried out 
between July 2017 and August 2018. The study was conducted within a single NHS Trust and 
podiatry team, but across seven different community care locations. The podiatry team 
consists of more than 20 members of staff, each of whom were involved in the clinical care 
and study’s infection appraisal process; the vast majority of staff have a minimum of ten 
years of experience as a podiatrist managing DFUs. Full approval was obtained from the 
national research ethics service (ref 17/LO/0703), health research authority, and hosting 
NHS Trust. Written informed consent was obtained from all participating patients, in 
accordance with the Declaration of Helsinki. Those eligible were diabetic patients aged 18 
years or older, having mental capacity to provide informed consent, with a clinical diagnosis 
of DFU that was being cared for by the podiatry service.  
A pragmatic approach was taken to allow the appraisal of the Glycologic detection kit in 
parallel to standard podiatry care of the DFU. As such, a cohort of 136 patients was seen at 
baseline and at a second visit approximately one week after the first baseline visit. The first  
37 patients were seen for a further three samplings/visits, each one circa one week apart 
from one another; this follow-up number was reduced to allow recruitment and sampling of 
a larger cross-section of patients in view of planned multiple regression analysis. If an 
infection was identified whilst any participant was enrolled, through either clinician opinion 
or Glycologic swab result, they were followed up for up to ten visits maximum or less if the 
wound was no longer infected (as determined by clinical opinion), had healed or the patient 
had to be referred to a specialist such as vascular surgery. Infected wounds were managed 
according to local clinical guidelines, with flucloxacillin prescribed as first line antibiotic 
therapy where possible and referral to tertiary services if required. 
Study dataset  
At each clinic visit, the podiatrist recorded whether they felt the wound was not infected, 
possibly infected, or infected. A clear definition of these three options was not given (i.e. 
they were not operationalised), since we wanted podiatrists to draw their own conclusions 
based on their assessment of the DFU wound; this is similar to standard clinical practice 
where predefined criteria are also not present. The podiatrist recorded this opinion prior to 
conducting the Glycologic test and was therefore essentially blinded to the test result. The 
order of events was therefore: a) podiatrist observes DFU and forms opinion on infection 
status, b) podiatrist takes wound swab for Glycologic test, c) researcher adds swab to 
Glycologic test tube and takes photos at 0 and 10 minutes, d) researcher and podiatrist 
agree on colour of Glycologic test result at 10 minutes. The following wound characteristics 
were recorded individually for each patient, as determined by the podiatrist: erythema 
around DFU (-/+/++, indicating absence, mild-moderate presence, and moderate-severe 
presence), purulence (-/+/++, grading as for erythema), odour (none, low, moderate, high 
degree of odour), patient perception of DFU pain (linear visual display score between 0 and 
10, with supporting emoticon faces). Patient demographics such as age, sex and BMI, and 
wound data such as chronicity, number of lesions, ulcer location, ulcer recurrence (same 
location, at least four weeks after being defined as healed), ulcer-related pain and use of 
prophylactic antibiotics (not necessarily prescribed for the index wound, and always 
instigated prior to enrolment into this study) were also recorded. Other variables that were 
collated included smoking status, alcohol consumption, and presence of neuropathy 
(evidenced by monofilament test).  Furthermore, vasculature-related co-morbidities were 
recorded and graded, with the most severe co-morbidity defining the grading. Their 
presence was based on confirmatory medical notes by GPs and hospital specialists. Classed 
as mild-moderate were type I diabetes, hypertension, chronic kidney disease (CKD) up to 
and including stage 3, retinopathy, varicose veins, atrial fibrillation, history of deep venous 
thrombosis, heart failure. Moderate-severe co-morbidities were history of myocardial 
infarction, stroke or transient ischaemic attack, CKD stage 4 or higher, peripheral vascular 
disease, history of amputation. This practical approach was taken to minimise the total 
number of variables to be included in inferential statistical analyses; a comprehensive 
published comorbidity score was not applied since the focus is on vascular health and not all 
non-vascular comorbidities were known for all patients. 
Since this study sought to appraise the performance of the Glycologic detection kit versus 
standard clinical judgement, overall management of the DFU, including microbiology testing 
of samples, use of off-loading, dressings, bandaging and antibiotic use was decided by the 
treating podiatrist and not influenced by the additional Glycologic test. 
Glycologic detection kit 
At present, the Glycologic infection detection kit is very similar in size and design to a 
standard CE-marked sterile swab used to obtain e.g. a wound exudate sample. The device 
contains two separate reagents, one in the clear plastic vial end and the other in a foil-
sealed compartment (seen in blue in Figure 1). Although the kit is stored between 2 – 8°C, 
which was monitored throughout this study, shortly before use it is brought up to room 
temperature to allow any reaction to take place at ambient temperature. In this study, this 
meant 10 minutes at room temperature. The sterile swab with the wound exudate sample is 
pushed into the device, breaking the foil-sealed compartment (which has foil at the top and 
bottom and therefore both solutions are sterile before used for diagnostics) and allowing 
the reagents to mix with the sample. The Glycologic diagnostic kit contains a substrate that 
is acted by a host factor contained in the patient’s wound exudate through a biochemical 
reaction. The 10 minute cut-off incubation period is designed to distinguish by a developing 
or diminishing state of infection (yellow result), and an active infection (orange-red result). 
If the test was to be incubated for longer then: a) a yellow result will eventually turn orange-
red, and b) the point-of-care  approach would be lost due to slower turnaround time. In 
clinic, the Glycologic detection kit is applied as follows: first, for comparison, a baseline 0 
minute photo is taken of the detection kit. Then, following initial debridement of the wound 
(including removal of any biofilm, and use of saline) a sterile swab is used to sample the 
wound according to the method described by Levine and colleagues.10 The middle of the 
wound is targeted and the sampling should be from surface of the wound, rather than 
exudate only. Care needs to be taken to avoid sampling (fresh) blood. The swab is then 
pierced through the two foil layers to mix the reagents; the swab is gently swirled for five 
seconds and then left to incubate for 10 minutes at room temperature, after which a photo 
is immediately taken. Depending on the degree of host response to infection, the solution 
can turn from colourless to either yellow or orange. 
Figure 1. Glycologic detection kit  




The primary outcome, presence and distribution of (potential) bacterial infection was used 
for sample size calculation. Based on one publication, incidence of infection is 9% over a 
two-year period.11 Therefore an approximate infection incidence of between 5% (‘opinion 
1’) to 9% (‘opinion 2’) – with a possibly infection rate for both of 10% - was assumed. A 
power calculation to achieve 80% power and 5% significance, based on two-sided Chi-
squared test, results in a sample size of 380 samples.  Descriptive statistics were used to 
parameters collated at baseline, such as wound characteristics and demographics.  Four 
inferential tests were deployed to explore the relationship in outcomes between clinical 
judgement, Glycologic kit detection testing, and wound infection status: Chi-squared test 
(cross-tabulation of clinical opinion and kit test results); logistic regression analysis and Cox 
regression analysis – using swab number as time variable for the latter – when the 
dependents were either clinical opinion (no infection vs possible/definite infection) or 
Glycologic test result (negative results vs yellow/orange results); and principal component 
analysis (PCA). To make the outcome the dependent outcome binary, possible and definite 
infection, and also yellow and orange colour change, were pooled and compared to a 
negative result.  All data was first collated in Microsoft Excel before analyses were 




The 136 consented patients provided a total of 383 DFU wound swabs. The number of 
participants per number of eventual swabs was as follows: one swab (n = 19); two swabs 
(70); three swabs (11); four swabs (4); five swabs (28); six swabs (1); seven swabs (2) and ten 
swabs (1).  Figure 2 shows a flowchart overview of how many patients were considered for 
the study, consented, and how many swabs were taken. Deviation from the planned two or 
five swabs happened due to loss to follow-up of patients and a positive clinical opinion or 
Glycologic kit result triggering a longer follow-up. In total, 628 patients who attended the 
clinics were considered for the study, of which 486 patients were not eligible (reasons 
include non-diabetic, no ulcer) and 6 eligible patients did not agree to take part. For 
enrolled patients who had multiple wounds, the largest wound was considered the index 
wound and the same wound was swabbed whilst the patient was in the study. Incorporating 
the Glycologic swab test proved relatively straightforward, since the DFU can be cleaned 
and re-dressed whilst the Glycologic incubation takes place. To allow the Glycologic tubes to 
stand upright and be photographed, a bespoke 3D-printed stand was produced. Table 1 
summarises the patient demographics for the study participants, whereas Table 2 focuses 
on the wound-related characteristics for each participant.  
 

































Assessed for eligibility (n = 628) 
Excluded (n = 492) 
• Did not meet inclusion criteria (n = 486) 
• Declined to participate (n = 6) 
Enrolled (n = 136) 
Swab 1 
o Glycologic kit used (n = 136) 
Swab 2 
o Glycologic kit used (n =117) 
o Lost to follow up (n = 8) 
o Healed (n = 8) 
o Deceased (n = 1) 
o Glycologic kit unavailable (n = 1) 
o Withdrawn (n = 1) 
Swab 3 
o Glycologic kit used (n = 48) 
o Healed (n = 3) 
Swab 4 
o Glycologic kit used (n = 37) 
o Lost to follow up (n = 2) 
o Healed (n = 3) 
Swab 5 
o Glycologic kit used (n = 31) 
o Healed (n = 2) 
o Patient no longer eligible (n = 1) 
Swab 6 
o Glycologic kit used (n = 4) 
Assigned to 2-swab arm (n = 93) Assigned to 5-swab arm (n = 43) 
As planned (n = 136) 
As planned (n = 117) 
o Hospital admission (n = 3) 
o Under care of district nurses (n = 2) 
o Stopped attending podiatry (n = 3) 
 
o As planned (n = 37) 
o Extra (n = 11) 
 
 
o As planned (n = 32) 
o Extra (n = 5) 
 
 o Hospital admission (n = 1) 
o Under care of district nurses (n = 1) 
o As planned (n = 30) 
o Extra (n = 1) 
 
 
Extra (n = 4) 
 
Swab 7 
o Glycologic kit used (n = 3) 
Swab 8 
o Glycologic kit used (n = 1) 
Extra (n = 3) 
 







Table 1, Patient demographics 
variable Mean; 95% CI (SD) 
Age, years  70; 67-72 (14) 
Height, m 1.72; 1.70-174 (0.10)  
Weight, kg 93; 89-98 (25)  
BMI  31; 30-32 (7) 
Alcohol consumption, U/week 4.2; 2.5-59 (9.9) 
 n [%] 
Smoking status  Never:         63 [46%] 
Ex-smoker: 52 [38%] 
Current:      21 [15%] 
Sex Male:           92 [68%]  
Female:       44 [32%] 
 
Table 2, Ulcer characteristics and vascular health status 
Item n [%] 
Ulcer location (calcaneus, digital, lateral, plantar, 
dorsal, n [%]) 
Calcaneus:            19 [14%] 
Digital:                   70 [51%] 
Lateral:                  14 [10%] 
Plantar:                 25 [18%] 
Dorsal:                     8 [6%] 
Ulcer duration                                  16; 8-24 (47)* 
Ulcer recurrence  Yes:                         44 [32%] 
Number of lesions  One:                      102 [75%]  
2-3:                          32 [24%] 
>3:                             2 [1.5%] 
Systematic prophylactic antibiotics use  No:                        109 [80%]  
Yes:                         27 [20%] 
Neuropathy  No:                           79 [58%]  
Yes:                          57 [42%] 
Vascular co-morbidities  None:                         8 [6%] 
Mild-moderate:     68 [50%] 
Moderate-severe: 60 [44%] 
 *mean weeks; 95% CI (SD) 
Swab 9 
o Glycologic kit used (n = 1) 
Swab 10 
o Glycologic kit used (n = 1) 
Extra (n = 1) 
 
Extra (n = 1) 
 
The distribution of clinical opinion versus Glycologic test outcome was compared and 
analysed with the Chi-squared test. Table 3 shows that there is a significant difference in 
distribution of the two outcome measures. Overall agreement was seen in 301 (78.6%) of 
wound swab cases. An outcome of either possible infection or definite infection was 
concluded more often by podiatrists when the corresponding Glycologic result was 
negative, when compared to vice versa. Numerically, this meant that 56 [14%] of clinical 
opinion samples were (possible) infections and 14 [3.7%] of the Glycologic test result were 
positive through chromatic colour change. For the clinical opinion sample this is higher than 
some published rates11,12 and similar to a more recent publication13 but repeat swabs on the 
same patients contribute to an increased rate in positive results. Figure 3 show a 
representative example of a yellow and orange outcome with the Glycologic test kit after 
incubation for 10 minutes. 
 
Figure 3, representative results with Glycologic test kit 




Cox multiple regression, using the swab number as the time reference, and multiple logistic 
regression analyses were performed for both clinical opinion and Glycologic result as the 
dependent. Backwards likelihood ratio elimination was applied to determine which variables 
– listed in the Methods section - were most-significantly associated with a change in clinical 
opinion or Glycolologic test result. An increase in the number of lesions (p-value and 
severity of vascular co-morbidities were positively significantly associated with a positive 
Glycologic result, but not with the clinical opinion result. Conversely, females, smokers and 
high DFU pain scores showed a negative association with a positive Glycologic result. The 
variable ‘patient height’ produced aberrant results – an odds ratio of virtually zero - and was 
excluded. Clinical signs such as erythema, purulence and odour are significantly associated 
with both outcome measures, as outlined in Tables 4 and 5. Due to the applied backward 
elimination process, non-significant associations are not shown.  Prophylactic antibiotic use 
was not associated with a positive Glycologic result (HR 1.66 , 95% CI 0.57-4.80, p-value 
0.35) nor clinical opinion for the presence of infection (HR 1.59 , 95% CI 0.55-4.66, p-value 
0.40) , and was therefore eliminated in the Cox multiple regression analysis presented in 
Table 4.   
Prior to performing PCA, the factorability of the dataset was assessed. The Kaiser-Meyer-
Olkin measure of sampling adequacy indicated that the strength of the relationships among 
variables was moderate (KMO = 0.51), and Bartlett’s test of sphericity was significant (χ2 
(153) = 2518.59, p<0.001), indicating that the data were suitable for PCA. Parallel analysis 
recommended that six components be extracted from the data.14  A PCA was performed 
using varimax rotation, with the six components explaining 59.84% of the variance. Given 
the fairly large sample size, items were considered to load onto a component if their loading 
was ≥ 0.32; all items had primary loadings over this value. 15 One item had a cross-loading 
above 0.32 (“glycologic colour change”). The loading matrix is presented in Table 6. 
Labels have been provided for the 6 components, based on an interpretation of the items 
that constitute them. One item in particular had strong cross-loading between factors 
(“glycologic colour change”). The first component was termed “Signs of infection”, the 
second “Lifestyle”, the third “Physical patient profile”, the fourth “Lifestyle and wound 
profile”, the fifth “Patient’s vascular health” and the sixth “Ulcer duration and antibiotics 
use”. 
 
Table 3, Clinical opinion and Glycologic test outcome; comparison of respective results  
Clinical opinion  Glycologic test result 
Clear, n [%]  Yellow, n [%]   Orange, n [%] 
Not infected, n [%] 293 [77%] 13 [3.4%] 1 [0.3%] 
Possibly infected, n [%] 33 [8.6%] 5 [1.3%] 3 [0.8%] 
Infected, n [%] 23 [6.0%] 9 [2.3%] 3 [0.8%] 
p-value < 0.001 (Chi-squared test) 
 
Table 4, Cox regression analysis, with Glycologic test result or clinical opinion as the 
dependent and swab number as time reference 
Variable Hazard ratio 
(HR) 
95% CI  p-value 
Dependent: Glycologic test result 
Sex 0.063 0.01 – 0.41 0.004 
Weight 1.019 1.00 – 1.04 0.046 
Smoking status 0.46 0.25 – 0.87 0.016 
Number of lesions 4.18 2.06 – 8.48 <0.001 
Vascular co-morbidity 2.70 1.12 – 6.54 0.028 
Erythema 3.76 2.10 – 6.74 <0.001 
Odour 1.92 1.25 – 2.96 0.003 
DFU pain scale score 0.74 0.61 – 0.89 0.002 
Dependent: clinical outcome 
Erythema 4.23 2.90 – 6.16 <0.001 
Purulence  1.42 1.00 – 2.01 0.049 
CI = Confidence interval. Backwards stepwise elimination of non-significant variables.  
 
Table 5, Binary logistic regression analysis, with Glycologic test result or clinical opinion as 
the dependent  
Variable Odds ratio (OR) 95% CI  p-value 
Dependent: Glycologic test result 
Number of swabs 1.58 1.22 – 2.05 <0.001 
Patient age 0.94 0.90 – 0.99 0.023 
Sex  0.025 0.003 – 0.22 0.001 
Weight 1.02 1.00 – 1.05 0.047 
Smoking status 0.35 0.15 - 0.79 0.011 
Number of lesions 10.42 3.82 – 28.37 <0.001 
Vascular co-morbidity 2.43 0.96 – 6.13 0.061 
Erythema 4.32 1.92 – 9.69 <0.001 
Purulence  2.96 1.16 – 7.57 0.023 
Odour 2.20 1.20 – 4.02 0.010 
DFU pain scale score 0.74 0.58 – 0.94 0.012 
Dependent: clinical outcome 
Sex 4.23 1.29 – 13.86 0.017 
Alcohol consumption 1.04 1.00 -1.07  0.039 
Erythema 9.84 4.85 -19.96  <0.001 
Purulence  4.55 2.21 -9.34  <0.001 
Odour  2.83 1.28 -6.27  0.010 
DFU pain scale score 1.22 1.07 -1.38  0.002 
Glycologic result 3.32 1.28 -8.58  0.014 
CI = Confidence interval. Backwards stepwise elimination of non-significant variables.  
 
Table 6, Principal component analysis – rotated component matrix (0.32 as cut-off) 

































clinical opinion 0.84      
erythema 0.74      
purulence 0.67      
odour 0.63      
glycologic colour change 0.46    0.44  
BMI  0.92     
weight  0.89 0.36    
alcohol consumption  -0.38 0.35 0.32   
sex   -0.90    
height   0.85    
neuropathy    0.67   
patient age    -0.59   
pain scale score    -0.58   
number of lesions     0.73  
vascular co-morbidity     0.53  
number of swabs    0.39 -0.41  
ulcer duration      0.72 




In this study the performance of a novel point-of-care infection detection kit, which 
measures host-response to pathogenic levels of bioburden and displays its result through a 
chromatic colour change, was appraised in patients with DFU and compared to clinical 
opinion regarding the presence of wound infection. The podiatrists based their opinion on 
the presence of recognised clinical signs of infection. On the other hand, a positive result 
from the Glycologic kit is reliant on an active host response (i.e. internal cell signalling) to 
the presence of bacteria in a wound. Therefore, the clinical opinion utilised in this study 
works to the recommended diagnostic approach to detecting diabetic foot infection16,17,18. 
The Glycologic test correlates with clinical signs of infection too, but also to other factors 
(vascular comorbidity and number of DFU lesions). Pain, the single component associated 
with prediction of clinical infection of chronic wounds in a meta-analysis conducted by 
Reddy and colleagues19, produced conflicting results in our study. This may be due to the 
presence of neuropathy in some patients, making the DFU less painful compared to for 
those patients who do not have neuropathy - even if the wound is infected. The Glycologic 
kit substrate is not designed to detect or predict pain levels in patients.  
The key differences between clinician opinion and the Glycologic test result are: clinicians 
identify an infection more often than the Glycologic kit; the Glycologic kit sometimes 
identifies an infection where the clinician does not, and vice versa; and a positive result for 
the Glycologic kit is associated with poorer vascular health, in addition to established clinical 
signs of infection. The results in this study indicate that it is not necessarily the recurrence 
or chronicity of a wound, or a patient’s lifestyle, that increases the risk of wound infection, 
but rather a poorer (vascular) health status. This corroborates with previous literature 
suggesting that bioburden itself is not necessarily sufficient for true infection to occur in a 
wound; instead, another factor such as poor vascular supply may be required to trigger 
this.20,21 It should be noted that our classification of vascular co-morbidity applied in this 
study is not a recognised scoring approach like that by Charlson or Elixhauser22, but rather a 
pragmatic categorisation of different conditions affecting the vascular system. Ndosi and 
colleagues23 also observed that multiple lesions are associated with increased infection and 
poorer healing. We found that a positive Glycologic test result was significantly associated 
with patients having more than one DFU, though this was not observed when clinical 
opinion of infection was the outcome measure. Due to intellectual property and commercial 
sensitivities, the molecular process that underpins the colour change in the test kit cannot 
be disclosed by Glycologic Ltd. Therefore, a detailed discussion on any relationships 
between bioburden and host-related inflammatory and wound healing processes are not 
possible. However, it is known that the host-produced molecule involved in the kit reaction 
is produced in chronic wounds where the host deems the bioburden to be pathogenic. 
Apart from the Glycologic kit, various approaches to develop a point-of-care test for chronic 
wound infection are being developed and appraised, and this molecular approach is 
anticipated to be introduced in clinical practice in the near future.24,25,26,27 
There are a few practical drawbacks to the study which should be taken into account. Firstly, 
at present, the Glycologic test kit does not include a negative or – perhaps more importantly 
- positive control. Therefore, if there is no colour change the clinician needs to have faith 
that there is genuinely no host-response to infection present. However, if the kit solution 
has expired or is not at room temperature then this may lead to false-negative outcomes. 
Another aspect around the colour indication is that those who perform the test need to be 
vigilant that a wound swab does not contain significant amounts of blood, since doing so will 
contaminate the Glycologic test solution and render it pink. In our experience a small degree 
of blood contamination did not hinder the test interpretation. Secondly, in this study a 
comparison of Glycologic test result versus microbiological results of a wound swab was not 
performed. The reason for this was pragmatic; as part of standard practice, podiatrists do 
not routinely send samples to the microbiology laboratory for testing.  In fact, in only 15 out 
of 383 (4%) wound swabs was a microbiology sample processed. This therefore made the 
sample too small to be included in the analyses for this present study. Having a point-of-
care test to hand may assist clinical staff in obtaining a chromatic result to determine if a 
chronic wound is infected. It may also provide physical evidence to patients and for medical 
notes. However, a microbiology sample would still need to be obtained from confirmed 
infected wounds for antibiotics sensitivity testing; the Glycologic diagnostic kit does not 
identify what type of bacteria may be causing the infection. In relation to how the study 
sample represents the wider patient population, a few observations can be made. Although 
a mix of males and females with varying BMI, smoking status and co-morbidities were 
included in the study, the ethnicity of all patients was white British.  
From the results obtained in this study, we cannot say if the Glycologic test kit challenges 
the paradigm around wound assessment in which quantification of bioburden is deemed the 
gold standard for determination of wound infection.28 To ascertain if this is the case, more 
research is indicated where microbiological samples are compared to both clinical opinion 
and the Glycologic kit. It is important to stress, however, that the biochemical reaction 
between the substrate in the Glycologic test tube and the host factor in the patient’s wound 
exudate is not dependent on presence of bacteria per se. It is the effect that bacteria have 
on the host’s immune and inflammatory responses that drives the eventual reaction in the 
Glycologic diagnostic kit. This present study indicates that the Glycologic test result 
corresponds with a clinician’s opinion of wound infection presence; it is not known if there 
is any correlation between a positive Glycologic test result and the degree of bacterial load 
in a wound. For further validation of the Glycologic kit, a comparison to microbiology swab 
or tissue sampling results is indicated. Finally, different cytokines and other biomarkers can 
be elevated and suppressed differently, depending on the type of chronic wound.29  Thus, 
other wounds need to be assessed with the Glycologic kit, including chronic non-diabetic 
ulcers, pressure ulcers and non-healing post-surgical wounds, to determine if the results 
obtained for DFUs are also observed in other wound types and in patients with different 
(non-vascular) co-morbidities.  
Conclusions 
This study demonstrates that it is relatively straightforward to incorporate the Glycologic 
point-of-care test kit in a clinical care setting, albeit as part of a clinical research project. 
Results demonstrate that the Glycologic test results for DFU wound swabs mostly agree 
with clinical opinion, though the test kit appears to be more conservative in terms of the 
identification of infection. Furthermore, the Glycologic test kit’s colour change is associated 
with the clinical signs and symptoms of infection – namely erythema, purulence and odour – 
and apparently also indicators of a patient’s poor (vascular) health, such as the presence of 
numerous DFU lesions and/or co-morbidities such as peripheral vascular disease or severe 
chronic kidney disease. These outcomes suggest that a host-response to bioburden may be 
a patient-specific event rather than something where – for example - a generalised lower 
limit threshold can be applied. Further research appraising the performance of the 
Glycologic test kit in patients with other wounds, and a wider comparison of outcomes 
involving clinical opinion and microbiological assessment results will inform how the 
Glycologic test performs and how its results may be interpreted for clinical application. 
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